Aurobindo Pharma, Jubilant Rated New ‘Buy’ at Goldman Sachs

Aurobindo Pharma Ltd. and Jubilant Life Sciences Ltd. were rated “buy” in new coverage at Goldman Sachs Group Inc., which cited an improving revenue outlook, greater capacity utilization and easing balance sheet concerns.

The brokerage has a share-price estimate of 1,545 rupees for Aurobindo Pharma and a forecast of 408 rupees for Jubilant Life Sciences, according to a report by analysts including Balaji V. Prasad.

Before it's here, it's on the Bloomberg Terminal. LEARN MORE